Make your MedTech start-up attractive for strategic buyers
A guide for MedTech CEOs, Founders — and anyone who wants to build something worth investing in.
As a MedTech Advisor, I'm somewhere between 30 and 40 founder conversations every quarter. Around 70% of those companies are missing the same things — and none of them are on the technology side.
Every time a MedTech start-up gets acquired for a significant number, LinkedIn floods with posts about whatever narrative happens to be hot that week. AI, digital health, the next big wave. Everyone rushes to align themselves with the story.
I’ve been watching this pattern for years, and what I can tell you (from inside of the advisory conversations that don’t make it onto LinkedIn banners) is:
the companies behind those headlines didn’t get there because they followed a “trend”.
They got there because they made a set of decisions, years earlier, that most Founders either don’t know about or keep postponing. They got there by building something that a strategic buyer couldn’t say no to, on every dimension that matters: reimbursement, evidence, team, brand, financial structure, and market access.
Those things are not “exciting” to post about, I know, but they are - however - the difference between a company that gets a call, and one that spends years waiting for one that never comes.
So let me walk you through the mindset and the elements that often get missed.
Before anything else, let’s look at where we actually are in 2026: record money, minimal volume, capital concentrating into fewer assets. This is not a market filled with opportunities for everyone. This is a highly challenging market that rewards a tiny number of exceptional companies and quietly passes on the rest.
In practice, that means the bar for what counts as fundable or acquirable has moved significantly — while most Founders are still playing by 2021 rules. If you’re building right now, you need to understand which side of that line you’re on.
The answer, in two words: de-risked execution.
Large companies come to small players because they want growth, because they want an asset that has largely been de-risked. This is one element that should sit at the core of your business.
Ignore the trends. Seriously.
What is trending in conference keynotes and LinkedIn posts is not the same thing as what creates acquisition value. Those are two completely different markets. One is attention, the other one is capital.
AI in MedTech is everywhere: digital health platforms, remote patient monitoring, precision diagnostics etc. Real fields, real opportunities. But also fields where hundreds of companies are piling in because the narrative is loud, not because they have a specific clinical insight, a specific capability, or an unfair advantage in that space.
Strategic buyers are looking for something far more boring and far more valuable: a company that found a real market opportunity, built conviction based on what they actually know and are uniquely positioned to do, and then executed with enough discipline that the results speak for themselves.
The Founders who exit well are almost always the ones who ignored the noise and stayed focused on something specific: a clinical problem they understood deeply, a market they had relationships in, a capability nobody else had.
Follow the real opportunity, not the story of the opportunity.
What strategic buyers are looking for
When Medtronic, Boston Scientific, Stryker looks at your start-up, they are not having a conversation about innovation. They are having a conversation about risks. The meta-question every internal BD team has to answer before any process moves forward is this:
Is it faster, cheaper, and lower-risk to acquire this company than to build the same capability ourselves?
And in 2026, two other questions sit next to it:
Does this asset align with where our defined business units are going over the next five years?
Can we absorb them into our existing portfolio quickly?
Both of those questions need a clear yes before anyone gets on a plane.
Nobody is looking into near-term revenue contribution. Strategic fit doesn’t just mean “your product is adjacent to ours.” It means that your technology, your clinical data, your market access, and your team can accelerate their business.
A very good example is Axonics, which was acquired by Boston Scientific in 2024 for $3.7 billion. Founded in 2012, FDA approved in 2019, targeting a therapy category that existed for decades. What Axonics did was take a real, validated clinical need and execute on it with such completeness that anybody could plug the entire company into their commercial infrastructure from day one. While other founders were chasing trends, they built a clean regulatory pathway, established reimbursement strategy, and got 100,000+ real patients. Recurring revenue growing at pace. A sales motion their reps could run immediately. A data room with no structural surprises.
That is not luck. This is business strategy executed over a decade of deliberate, compounding decisions and - of course - hard work.
Reimbursement is the entire strategy.
I have had this conversation more times than I can count. A Founder shows me a beautiful product, solid clinical rationale, clean regulatory pathway. And when I ask about reimbursement, they say: “We’re working on it.”
That phrase should terrify you. It terrifies me.
Reimbursement is not something you work on after the product is built and you’re running demos for doctors on it. It is something you design into the strategy from the very beginning — because a medical device without a billing code is not a product. It is a prototype with a CE mark.
Think about what happens when a clinician wants to use your device in a hospital system. The procurement committee asks how it gets paid for. If the answer is complicated, uncertain, or “we’re pursuing a new code,” adoption stalls. If adoption stalls, your commercial numbers don’t grow. If your commercial numbers don’t grow.. you know how this story ends.
In 2026, good US/EU reimbursement alignment is a major de-risking factor for any company looking to build in these two markets.
What “reimbursement execution” actually looks like:
Existing codes actively being billed. Payer coverage decisions in place in your key markets. A health economics study showing your device reduces costs or improves outcomes in a way payers care about. Commercial accounts that are billing successfully.
Not a slide that says “reimbursement path identified.” Actual billing data. Actual payer conversations. Actual numbers.
Financial discipline — probably the hardest part for Founders
Strategic buyers aren’t just evaluating your clinical story, but they’re looking for the quality and predictability of your business. Subscription-based or usage-driven models are significantly more attractive than one-time capital equipment sales (because it’s forecastable).
Healthy gross margins matter enormously. A product with strong clinical outcomes and thin margins creates post-acquisition headaches that the buyer has to fix.
Validated cost savings or reduced clinician workload are extraordinarily powerful right now. This is not just a clinical talking point, it is a story that payers respond to, that procurement committees use to justify the purchase, and that a buyer’s existing sales team can take into their current conversations.
It’s no longer about product + service anymore. It needs to be about the services & solutions delivered as an ongoing experience that creates continuous value and continuous revenue.
Most early-stage MedTech companies price their device, add a training fee, and call it a business model. That is not recurring revenue. That is a one-time sale with a support ticket and you are building a different kind of asset than what strategic buyers are actively looking for.
Stop selling a product. Build a solution they can plug in.
A product is something a buyer has to figure out how to place inside their existing portfolio. A solution, built around a product, with clinical training, service infrastructure, workflow integration, and a reimbursement story that works — is something they can plug directly into their commercial engine and make it productive from day one.
Think about it from the acquirer’s side. They have established sales reps with relationships in specific clinical departments, they have distributor agreements, they have hospital partnerships already in place.
What integration-ready actually looks like: A clinical training program that gets a sales rep productive in under 90 days. A workflow or data integration that connects with EHR systems the acquirer already uses. Patient outcomes data that continues generating real-world evidence on an ongoing basis, not just at launch.
Each of these reduces integration cost, compresses time-to-value for the buyer, and increases what they are willing to pay.
Brand, KOLs, and partnerships. This is your commercial infrastructure.
I've watched a Founder spend 3 years building something genuinely important, get to the point where a strategic buyer was circling — and lose the conversation because nobody on the buyer's clinical team had ever heard of them. Because they had built in silence and they were invisible.
That thinking is expensive. Not in a metaphorical sense. In a literal, euro-and-dollar sense.
Brand in MedTech is not about just “looking good”! It is about being known by the right people before you need them to know you. And partnerships are not just distribution deals, they are third-party proof that your product works in the real world, integrates into existing workflows, and was credible enough for someone else to bet their reputation on.
When a corporate development team evaluates acquisition targets, they are not just reading your financials. They are calling the KOLs they know: “Have you heard of this company? Do you use their product? What do the surgeons say?” They are checking whether your name comes up at the right congresses without you being in the room. They are looking at which hospital systems work with you and whether those are relationships they would want access to.
This takes years to build. Years.
An advisory board strategy requires 18 to 24 months of cultivation before it produces real commercial impact. Starting when you think you need it is already too late.
A strategic partnership is not just a commercial win. It is a proof point, a de-risking mechanism, and an acquisition signal.
You open doors they can’t open on their own
This is the dimension I think is most underestimated by Founders building in MedTech. Large companies have extraordinary reach, but they also have extraordinary inertia. Getting inside a new hospital system, a new clinical department, a new geography takes them a long time (procurement politics, change management cycles, long sales cycles, internal slow decisional process).
You, as a start-up, can sometimes move in spaces they can’t. You built relationships with a specific clinical community before that community was commercially important. You got into hospital networks that weren’t on anyone’s radar three years ago. You have direct access to decision-makers that their national accounts team has been trying to reach for 18 months.
That is a real, dollar-value asset. The question you want a buyer asking internally is: “How long would it take us to build what they already have?”
If the honest answer is three to five years and tens of millions in commercial investment — the acquisition price starts to look very rational.
You are not selling them a product. You are selling them a shortcut to market access they cannot build that fast on their own.
Your data room is who you actually are
You can have a great product, strong revenue, real brand recognition — and still kill a deal in due diligence.
A data room is the moment a buyer’s team starts verifying your story, and the gap between your story and your documentation is where deals frequently die.
IP with unclear ownership. Clinical claims not backed by the scientific data. Financial records that are clean in the summary but messy in the detail. Reimbursement codes gaps or regulatory submissions unfulfilled. Key person dependencies with no succession plan. And in 2026, new on the list: AI-embedded products without documented validation pathways, cybersecurity gaps, or missing interoperability compliance.
Most of these problems don't arrive with a warning label. IP ownership gets blurry when a co-founder leaves and the assignment paperwork was never properly done, clinical claims drift when marketing writes copy based on pilot data the submission doesn't fully support.
Most Founders only look at their data room when they’re in an active M&A process. By then, it is too late to fix the structural things. You can clean up documents. You cannot retroactively build two years of clean financials, resolve an IP dispute, or generate the clinical evidence you never ran.
Data room readiness is a governance discipline. You build it over years, not in a sprint when someone calls you.
The team — because none of this happens without the right people
Every single thing I’ve described above (reimbursement strategy, financial discipline, solution architecture, brand building, data room quality) happens because the team understood it mattered, planned for it, and executed on it.
That does not happen by accident, and a buyer who does proper diligence can tell the difference between a team that built something deliberately and a team that got lucky. That distinction is worth real money.
When a strategic acquirer looks at your leadership team, they are asking a very specific question:
Do these people know what they are doing?
Not in a generic sense. Specifically: do they understand the regulatory landscape they are operating in? Do they know how hospital procurement works? Have they built clinical evidence pipelines before? Do they have real relationships in the clinical community? Can they run a division of our company?
There is also a practical post-acquisition question that rarely gets discussed openly: if the value of your company is partly in market access and clinical relationships, and those relationships live in the heads of two or three people who might leave — that is a risk flag, not an asset. A team with documented processes, distributed relationships, and clear succession thinking is a fundamentally different acquisition target.
The best team signals are not on your org chart. They are in the decisions that were made three years before the acquisition conversation started. The reimbursement strategy that was built early. The brand that was invested in before anyone asked for it. The data room that was kept clean from the beginning. The commercial model that was built to scale beyond the founding team.
A buyer doing serious diligence will find all of it, and they will price it accordingly.
One more thing
Founders who have spent four or five years building their technology sometimes have a genuinely hard time hearing that what they built is not acquisition-ready. Because they have invested everything: their time, their money, years of their life, and the investment feels like proof that the value is there.
A buyer does not see it that way. A buyer sees the risk that remains — not the effort that was spent. Those are completely different calculations.
If your target horizon is an acquisition in four to five years, the reimbursement strategy needs to start now. The brand and KOL work needs to start now. The data room discipline needs to start now. The commercial model architecture needs to start now.
Start looking at your company through a buyer’s eyes right now. Not the optimistic version, but the critical one.
Ask yourself: if I were a corporate development director at a very large MedTech company, what would make me hesitant? What would I flag as a risk? What would I need to see that I don’t see yet?
Answer those questions honestly. Then go and fix the answers.
If this landed — share it with a founder who needs to read it before someone else has to tell them the hard way.
Which part are you most behind on right now? Drop it in the comments. I read everything.
Hi, I’m Alina. I am the Editor of AliDrg MedTech Insights. When I’m not publishing here, I work with MedTech Founders and C-level executives on the things that make or break a company before it’s visible from the outside. If you would like to talk or if you have a great story to tell: